NanoViricides is trading at $1.42, up 10.55%, alongside an update that its NV-387 Phase II Ebola trial is proceeding as designed. - On October 5, 2026, the company said Phase IIA enrollment had been underway since around September 23. - The phase focuses on cautious enrollment, safety and dose selection; it is not designed to establish efficacy. - Available coverage does not independently confirm the precise intraday price response.